Drugs / EGEN-5784
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07429838 | Jun 2026 → Dec 2027 expected | hepatic encephalopathy, liver disorder | eGenesis, INC | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | eGenesis, INC | Regulatory eGenesis and OrganOx Announce U.S. FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure egenesisbio.com ↗
the U.S. Food & Drug Administration (FDA) has cleared the investigational new drug (IND) application for EGEN-5784 |
| 2024-01-19 | eGenesis, INC | Results eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor egenesisbio.com ↗
Stable blood flow, pressure, and pH were maintained throughout the procedure, in addition to robust bile production. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | eGenesis, INC | eGenesis and OrganOx Announce U.S. FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure egenesisbio.com ↗ |
| 2024-01-19 | eGenesis, INC | eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor egenesisbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGEN-5784 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07429838 ↗ |